Evidence map›Paper›PMID 26292326›Full record

ArticleJournal of virology2015

Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection.

Mauricio A Martins, Damien C Tully, Michael A Cruz, Karen A Power, Marlon G Veloso de Santana, David J Bean, Colin B Ogilvie, Rujuta Gadgil, Noemia S Lima, Diogo M Magnani and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Journal of virology · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

Mauricio A MartinsDepartment of Pathology, University of Miami, Miami, Florida, USA mmartins@med.miami.edu.
Damien C TullyRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Michael A CruzDepartment of Pathology, University of Miami, Miami, Florida, USA.
Karen A PowerRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Marlon G Veloso de SantanaDepartment of Pathology, University of Miami, Miami, Florida, USA.
David J BeanRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Colin B OgilvieRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Rujuta GadgilRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Noemia S LimaLaboratório de Biologia Molecular de Flavivirus, Instituto Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brazil.
Diogo M MagnaniDepartment of Pathology, University of Miami, Miami, Florida, USA.
Keisuke EjimaSection on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
David B AllisonSection on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael PiatakAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.
John D AltmanDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Christopher L ParksInternational AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn Army Terminal, Brooklyn, New York, USA.
Eva G RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Saverio CapuanoWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ricardo GallerInstituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Myrna C BonaldoLaboratório de Biologia Molecular de Flavivirus, Instituto Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brazil.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.
Todd M AllenRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
David I WatkinsDepartment of Pathology, University of Miami, Miami, Florida, USA.
Ragon Institute of MGH, MIT and Harvard · USUniversity of Miami · USFundação Oswaldo Cruz · BRLeidos (United States) · USUniversity of Alabama at Birmingham · USUniversity of Wisconsin–Madison · USEmory University · USInternational AIDS Vaccine Initiative · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Recognition of HIV-1 by Innate Immunity Receptors during Primary InfectionP01AI074415 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2008 to 2013
$17.3M
The Functional Significance of CTL EscapeR37AI052056 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2008 to 2017
$7.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI074415NIAID NIH HHS R37 AI052056NIAID NIH HHS R37AI052056NIH HHS P51 OD011106
6 · The paper itself

Abstract

unlabelledCertain major histocompatibility complex class I (MHC-I) alleles (e.g., HLA-B*27) are enriched among human immunodeficiency virus type 1 (HIV-1)-infected individuals who suppress viremia without treatment (termed "elite controllers" [ECs]). Likewise, Mamu-B*08 expression also predisposes rhesus macaques to control simian immunodeficiency virus (SIV) replication. Given the similarities between Mamu-B*08 and HLA-B*27, SIV-infected Mamu-B*08(+) animals provide a model to investigate HLA-B*27-mediated elite control. We have recently shown that vaccination with three immunodominant Mamu-B*08-restricted epitopes (Vif RL8, Vif RL9, and Nef RL10) increased the incidence of elite control in Mamu-B*08(+) macaques after challenge with the pathogenic SIVmac239 clone. Furthermore, a correlate analysis revealed that CD8(+) T cells targeting Nef RL10 was correlated with improved outcome. Interestingly, this epitope is conserved between SIV and HIV-1 and exhibits a delayed and atypical escape pattern. These features led us to postulate that a monotypic vaccine-induced Nef RL10-specific CD8(+) T-cell response would facilitate the development of elite control in Mamu-B*08(+) animals following repeated intrarectal challenges with SIVmac239. To test this, we vaccinated Mamu-B*08(+) animals with nef inserts in which Nef RL10 was either left intact (group 1) or disrupted by mutations (group 2). Although monkeys in both groups mounted Nef-specific cellular responses, only those in group 1 developed Nef RL10-specific CD8(+) T cells. These vaccine-induced effector memory CD8(+) T cells did not prevent infection. Escape variants emerged rapidly in the group 1 vaccinees, and ultimately, the numbers of ECs were similar in groups 1 and 2. High-frequency vaccine-induced CD8(+) T cells focused on a single conserved epitope and therefore did not prevent infection or increase the incidence of elite control in Mamu-B*08(+) macaques. IMPORTANCE: Since elite control of chronic-phase viremia is a classic example of an effective immune response against HIV/SIV, elucidating the basis of this phenomenon may provide useful insights into how to elicit such responses by vaccination. We have previously established that vaccine-induced CD8(+) T-cell responses against three immunodominant epitopes can increase the incidence of elite control in SIV-infected Mamu-B*08(+) rhesus macaques—a model of HLA-B*27-mediated elite control. Here, we investigated whether a monotypic vaccine-induced CD8(+) T-cell response targeting the conserved "late-escaping" Nef RL10 epitope can increase the incidence of elite control in Mamu-B*08(+) monkeys. Surprisingly, vaccine-induced Nef RL10-specific CD8(+) T cells selected for variants within days after infection and, ultimately, did not facilitate the development of elite control. Elite control is, therefore, likely to involve CD8(+) T-cell responses against more than one epitope. Together, these results underscore the complexity and multidimensional nature of virologic control of lentivirus infection.

Indexed as

AnimalsBase SequenceCD8-Positive T-LymphocytesDNA PrimersEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-B27 AntigenHumansMacaca mulattaMolecular Sequence DataReverse Transcriptase Polymerase Chain ReactionSAIDS VaccinesSequence Analysis, DNASimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusStatistics, NonparametricDNA PrimersEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-B27 AntigenNEF protein, SIVSAIDS VaccinesViral Regulatory and Accessory Proteins

Identifiers

PMID26292326
PMCPMC4621113
OpenAlexW2190522975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.